共 50 条
- [1] Efficacy of a Covalent ERK1/2 Inhibitor, CC-90003, in KRAS-Mutant Cancer Models Reveals Novel Mechanisms of Response and ResistanceMOLECULAR CANCER RESEARCH, 2019, 17 (02) : 642 - 654Aronchik, IdaDai, YuminLabenski, MattBarnes, CarmenJones, TerriQiao, LixinBeebe, LisaMalek, MehnazElis, WinfriedShi, TaoMavrommatis, KonstantinosBray, Gordon L.Filvaroff, Ellen H.
- [2] Selective, safe, scalable synthesis of a CC-90003, a covalent trifluoromethyl pyrimidine ERK 1&2 kinase inhibitorABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2017, 254Traverse, JohnHan, JianxinZou, NanfeiHeid, RichardFerretti, AntonioYong, Kelvin
- [3] A phase Ia study of CC-90003, a selective extracellular signal regulated kinase (ERK) inhibitor, in patients with relapsed or refractory BRAF or RAS-mutant tumors.JOURNAL OF CLINICAL ONCOLOGY, 2017, 35Mita, Monica M.LoRusso, PatriciaMcArthur, Grant A.Kim, Edward S.Bray, Gordon L.Hock, Nanette H.Laille, Eric J.Aronchik, IdaFilvaroff, EllenWu, XiaolingBendel, Johanna C.
- [4] Fragment-based discovery of a highly potent, orally bioavailable ERK1/2 inhibitor that modulates the phosphorylation and catalytic activity of ERK1/2MOLECULAR CANCER THERAPEUTICS, 2018, 17 (01)Heightman, Tom D.Berdini, ValerioBraithwaite, HannahBuck, IldikoCassidy, MeganCastro, JuanCourtin, AurelieDay, JamesEast, CharlotteFazal, LynseyGraham, BrentGriffiths-Jones, CharlotteLyons, JohnMartins, VanessaMuench, SandraMunck, JoanneNorton, DavidO'Reilly, MarcPalmer, NickPathuri, PujaReader, MikeRees, DavidRich, SharnaRichardson, CarolineSaini, HarpreetThompson, NeilWallis, NicolaWalton, HughWilsher, NicolaWoolford, AlisonMurray, Chris
- [5] Discovery and characterization of AZ6197, a potent and selective ERK1/2 inhibitorMOLECULAR CANCER THERAPEUTICS, 2018, 17 (01)Flemington, VikkiSimpson, IainDavies, EmmaRobinson, DavidLindsay, NicolaHanson, LyndseyHopcroft, PhilipTonge, MichaelRoberts, KarenWard, Richard
- [6] Characterization of a novel ERK1/2 inhibitor, which modulates the phosphorylation and catalytic activity of ERK1/2MOLECULAR CANCER THERAPEUTICS, 2018, 17 (01)Munck, Joanne M.Berdini, ValerioBevan, Luke D.Braithwaite, HannahBuck, Ildiko M.Cassidy, MeganCastro, JuanCourtin, AurelieDay, James E.East, CharlotteFazal, LynseyGraham, BrentGriffiths-Jones, Charlotte M.Heightman, Tom D.Hindley, Chris J.Kidane, BirikitiKucia-Tran, JustynaLyons, John F.Martins, VanessaMuench, SandraMurray, Chris W.Norton, DavidO'Reilly, MarcPalmer, NickPathuri, PujaReader, MikeRees, David C.Rich, Sharna J.Richardson, Caroline J.Saini, Harpreet K.Shah, AlpeshStanczuk, LukasThompson, Neil T.Walton, HughWilsher, Nicola E.Woolford, Alison J.Wallis, Nicola G.
- [7] In-gel activity-based protein profiling of a clickable covalent ERK1/2 inhibitorMOLECULAR BIOSYSTEMS, 2016, 12 (09) : 2867 - 2874Lebraud, HonorineWright, David J.East, Charlotte E.Holding, Finn P.O'Reilly, MarcHeightman, Tom D.
- [8] Fragment-based discovery of an orally bioavailable ERK1/2 inhibitor which reduces the level of phosphorylated ERKABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2018, 256Norton, David
- [9] Suppression of astrovirus replication by an ERK1/2 inhibitorJOURNAL OF VIROLOGY, 2008, 82 (15) : 7475 - 7482Moser, Lindsey A.Schultz-Cherry, Stacey
- [10] Discovery of GDC-0994, a potent and selective ERK1/2 inhibitor in early clinical developmentCANCER RESEARCH, 2014, 74 (19)Robarge, KirkSchwarz, JacobBlake, JimBurkard, MichaelChan, JocelynChen, HuifenChou, Kang-JyeDiaz, DoloresGaudino, JohnGould, StephenGrina, JonasXin LinghuLiu, LichuanMartinson, MatthewMoreno, David A.Orr, ChristinePacheco, PatriciaQin, AnnRasor, KevinRen, LiShahidi-Latham, SheerinStults, JeffreySullivan, FrancisWang, WeiruYin, PeterZhou, AiheBelvin, MarciaMerchant, MarkMoffat, John G.